Milwaukee Revenue Vertical 
Gust
OCTOBER 12, 2011
To provide some reference points, I surveyed thirteen angels groups in North American to determine their recent experience in negotiating the pre-money valuation of pre-revenue companies. See the 2010 data reported here: Current Pre-money Valuations of Pre-revenue Companies. Pre-money Valuation of Pre-revenue Companies.
Gust
OCTOBER 16, 2012
This summer I conducted our third annual survey of the pre-money valuation of pre-revenue companies recently funded by angel groups in North America. For the first time, we asked for data from specific business sectors, as follows: All pre-revenue deals. Pre-revenue life Science, biotech and medical device deals. Average: 2.96.
Expert insights. Personalized for you.
125 
Let's personalize your content